Related posts

TSX and Dow gain for the weekEarnings extend rallyWall Street fades, but TSX rallies
Investor Insights

This summary was created by AI, based on 16 opinions in the last 12 months.

Experts have mixed opinions on Danaher Corp. Some view it as a valuable long-term investment, highlighting its transformation into a healthcare company and its potential in the life sciences and diagnostics industries. Others caution against its high valuation and suggest waiting for a price drop before buying. The company has reported good results but also issued disappointing guidance, leading to uncertainty about its future performance.

Consensus
Mixed
Valuation
Overvalued
BUY
Danaher Corp.
a dividend aristocrat

They raised their dividend by 12%, a sign of confidence in this great company. It was bad, now great. The lifesciences industry is bottoming now.

machinery
PAST TOP PICK
Danaher Corp.
(A Top Pick Jun 20/23, Up 17%)

In 2020 to 2022 there was an inventory shortage. 2023 was slow with research dollars starting to dry up. 2024 should be better with re-stocking gone, and as a picks and shovels player it will benefit from an aging population.

machinery
BUY
Danaher Corp.

When he recommended this last summer, he was expecting the glut in bioprocessing equipment to finally end. They reported good results last October, but lowered guidance. In late October, the entire sector seemed to find its footing when interest rates peaked, but was it out of the woods? Last week, DHR reported healthy revenue and earnings beats, but issued very disappointing guidance with organic revenue to be down YOY. Shares slid 5% in pre-markets. Turns out that management was merely being conservative. During the conference call, DHR said that the world ex-China should return to grow later this year as the inventory gut ends. So, but it now.

machinery
BUY ON WEAKNESS
Danaher Corp.

Cutting edge technology, but valuation very high. Would recommend waiting for shares to fall before buying. Good for long term investors, but better opportunities for investors out there at better prices. 

machinery
WEAK BUY
Danaher Corp.

Transformed from an industrial to healthcare. Life sciences, diagnostics, and biotech. Did well during pandemic. Post-pandemic headwinds, though still generating lots of cash. Attractive company, she owns TMO instead on valuation.

machinery
TOP PICK
Danaher Corp.

Pure-play life science company. Covid brought a bump in orders, sales, and earnings. Revenue to China has come off. The year's been hard. Future looks much better, as it will continue to be the fulcrum in drug discovery (testing) and manufacturing. Yield is 0.55%.

(Analysts’ price target is $232.30)
machinery
WEAK BUY
Danaher Corp.
DHR vs. TMO

TMO is a leader in life sciences and diagnostics. He recently added. The entire sector has some over-supply. This is the bottom of the cycle. Lower risk, less upside, more diversified. Historically, good at acquisitions. Good long-term hold, but right now it's all about waiting for funding to come back to the sector.

When the cycle turns, both will do well and will probably outperform.

machinery
COMMENT
Danaher Corp.

Historically, it's been a well-run company, making equipment that helps develop new drugs. But that history means nothing. All that matters now is how a company performs in its sector and any disappointing news (in the sector of company) means the stock get punished. Like Danaher.

machinery
TOP PICK
Danaher Corp.

Market's not liking the negative growth compared to the pandemic. China has impacted it, not as many IPOs. The market just needs to look beyond all this. High quality, grows by acquisition. Great CEO. In all the right places. Good time to take a look for long-term returns. A company like this is a 5-10 year hold. Yield is 0.41%.

(Analysts’ price target is $282.58)
machinery
TOP PICK
Danaher Corp.

They work with branded drugs and are integral to FDA approval of drugs. DHR products help product such drugs. $200 billion in drug earnings (from big pharma) that's about to come off-patent, and the generic companies will need DHR to help produce the generic versions. So, DHR benefits from the brands and the generics.

(Analysts’ price target is $274.42)
machinery
BUY ON WEAKNESS
Danaher Corp.

Does not own shares, waiting for price to fall.
Strong business that will perform well in the future.
Excellent assets. 
Wait before buying.

machinery
Unspecified
Danaher Corp.

It is in life science tools diagnostics. Biological drugs are one component and it has 75% in recurring revenue from re-usables. Should benefit from long term growth in personalized medicine.

machinery
BUY ON WEAKNESS
Danaher Corp.

Life science & environmental company.
High growth healthcare business.
Concern is that share price is too expensive.
Would wait for shares to fall before buying.
Price appreciation will be limited.

machinery
WATCH
Danaher Corp.

A healthcare company, offering services and consumables to that industry. Their diagnostics helped spike profits and shares. Has since pulled back. On her watch list, but the PE has always been too hight. The PE has declined though. Interesting.

machinery
COMMENT
Danaher Corp.

It had a nice surge in earnings but its shares are pulling back slowly to its FMV which had been up to 5 1/2 BV.

machinery
Showing 1 to 15 of 51 entries

Danaher Corp.(DHR-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 8

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 9

Stockchase rating for Danaher Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Danaher Corp.(DHR-N) Frequently Asked Questions

What is Danaher Corp. stock symbol?

Danaher Corp. is a American stock, trading under the symbol DHR-N on the New York Stock Exchange (DHR). It is usually referred to as NYSE:DHR or DHR-N

Is Danaher Corp. a buy or a sell?

In the last year, 9 stock analysts published opinions about DHR-N. 8 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Danaher Corp..

Is Danaher Corp. a good investment or a top pick?

Danaher Corp. was recommended as a Top Pick by on . Read the latest stock experts ratings for Danaher Corp..

Why is Danaher Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Danaher Corp. worth watching?

9 stock analysts on Stockchase covered Danaher Corp. In the last year. It is a trending stock that is worth watching.

What is Danaher Corp. stock price?

On 2024-04-12, Danaher Corp. (DHR-N) stock closed at a price of $239.95.